title: Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. AIEOP/FONOP-TMO group. Associzione Italiana Emato-Oncologia Pediatrica.
abstract: The purpose of this study was to assess the role of ABMT in children with ALL who are in 2nd CR after an early isolated CNS relapse. All children experiencing an isolated CNS relapse at 10 AIEOP centers (Associazione Italiana Emato-Oncologia Pediatrica) from 1986 to 1992 were eligible for this study. The series included 69 patients who relapsed within 3 years from diagnosis: 19 underwent ABMT, nine patients underwent ALLO-BMT from an HLA-identical sibling, and 41 received conventional chemotherapy (CHEMO). Statistical analysis was performed using a Cox's regression model, adjusting for the waiting time before transplantation and prognostic factors. The 5 years DFS was 56.3% (s.e. 12.3) for patients in the ABMT group. This compared favorably with the poor result (12.6% (s.e. 5.9)) seen in the CHEMO group. The risk of failures was reduced by one-third in the ABMT group as compared to the CHEMO group in the multivariate analysis (P < 0.01). In the ALLO group four out of nine patients were in CCR 4-5 years post-transplant. This study suggests that ABMT may also represent a valuable therapeutic choice for patients lacking a matched familiar donor in 2nd CR after an early isolated CNS relapse.
authors.affiliation: Centro Leucemie Infantili, Università di Padova, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Messina
authors.forename: M G
authors.initials: MG
authors.lastname: Valsecchi
authors.forename: M
authors.initials: M
authors.lastname: Aricò
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: F
authors.initials: F
authors.lastname: Rossetti
authors.forename: R
authors.initials: R
authors.lastname: Rondelli
authors.forename: S
authors.initials: S
authors.lastname: Cesaro
authors.forename: C
authors.initials: C
authors.lastname: Uderzo
authors.forename: V
authors.initials: V
authors.lastname: Conter
authors.forename: A
authors.initials: A
authors.lastname: Pession
authors.forename: G
authors.initials: G
authors.lastname: Sotti
authors.forename: G
authors.initials: G
authors.lastname: Loiacono
authors.forename: N
authors.initials: N
authors.lastname: Santoro
authors.forename: R
authors.initials: R
authors.lastname: Miniero
authors.forename: G
authors.initials: G
authors.lastname: Dini
authors.forename: C
authors.initials: C
authors.lastname: Favre
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: A M
authors.initials: AM
authors.lastname: Testi
authors.forename: B
authors.initials: B
authors.lastname: Werner
authors.forename: D
authors.initials: D
authors.lastname: Silvestri
authors.forename: A
authors.initials: A
authors.lastname: Arrighini
authors.forename: S
authors.initials: S
authors.lastname: Varotto
authors.forename: M
authors.initials: M
authors.lastname: Pillon
authors.forename: G
authors.initials: G
authors.lastname: Basso
authors.forename: L
authors.initials: L
authors.lastname: Zanesco
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008577:Meningeal Neoplasms / Q000401:mortality / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D014182:Transplantation, Autologous